Record revenue and royalties fail to lift Halozyme Therapeutics stock amid sustained technical weakness

Traders Union
All News
Companies
Halozyme Therapeutics slides 2.62% today

Highlights

HALO remains under sustained selling pressure, trading well below key moving averages across all timeframes.
Technical momentum is decisively bearish, with oversold readings and major trend indicators confirming strong seller dominance.
Price is expected to consolidate between $59.00 and $64.50, with a high probability of further downside if support fails.

At $61.63, HALO trades well below key moving averages—MA-20 at $65.32, MA-50 at $70.44, and MA-200 at $67.10—indicating sustained selling pressure in the short, medium, and long term. The Ichimoku Kijun stands at $66.88, now acting as immediate resistance above the current price. Near-term support is found at the MA-100 ($69.45), with key support lower at the 52-week low ($47.50). Immediate resistance levels appear at the Ichimoku Kijun ($66.88) and MA-200 ($67.10).

Momentum signals on D1 show persistent bearishness, with the MACD pointing to a strong downtrend and ADX confirming sellers’ control but not peak trend strength. Oversold readings are seen in the RSI (31.07), Stoch RSI (28.33), and CCI (–99.82), while BBP also indicates seller dominance. In today’s session, HALO is down 2.62%, landing at the very bottom of its weekly range and reflecting a strong intraday decline. Over the week, HALO has fallen $1.80 (2.84%) from the previous weekly close of $63.43, with weekly volatility at 6.11%. The sustained drop from the week’s high of $65.11 underscores a steady negative tone.

Looking ahead, the expected trading range for the coming week is $59.00 to $64.50, keeping the price between its 52-week low of $47.50 and high of $82.22. The probability of further declines is very high (more than 80%), as all major W1 signals (RSI, ADX, MACD, and MA-50) point to continued weakness or neutrality. In the baseline scenario, HALO is likely to consolidate between near-term support and resistance. A bullish scenario would require a move above $66.88, clearing initial resistance, while a bearish outcome could see the price slip below $59.00, reinforcing downside risk.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Halozyme Therapeutics completed the acquisition of Elektrofi to expand its drug delivery capabilities. As the company integrates these new technologies, investors should monitor upcoming announcements for potential impacts on Halozyme's competitive positioning within the healthcare sector.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.